Poseida Therapeutics Inc (PSTX)
3.19
-0.16
(-4.63%)
USD |
NASDAQ |
May 17, 16:00
3.19
0.00 (0.00%)
Pre-Market: 20:00
Poseida Therapeutics Cash from Investing (TTM): 67.55M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 67.55M |
December 31, 2023 | 39.13M |
September 30, 2023 | -94.47M |
June 30, 2023 | -83.10M |
March 31, 2023 | -207.01M |
December 31, 2022 | -203.33M |
September 30, 2022 | -117.64M |
June 30, 2022 | -44.63M |
March 31, 2022 | 97.12M |
Date | Value |
---|---|
December 31, 2021 | 222.38M |
September 30, 2021 | 270.55M |
June 30, 2021 | -24.65M |
March 31, 2021 | -73.93M |
December 31, 2020 | -204.43M |
September 30, 2020 | -242.10M |
June 30, 2020 | -16.20M |
March 31, 2020 | -48.17M |
December 31, 2019 | -42.46M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-242.10M
Minimum
Sep 2020
270.55M
Maximum
Sep 2021
-39.19M
Average
-46.40M
Median
Cash from Investing (TTM) Benchmarks
Biomea Fusion Inc | -0.499M |
Cartesian Therapeutics Inc | 5.883M |
Lantern Pharma Inc | -0.5255M |
NovaBay Pharmaceuticals Inc | 1.062M |
Palatin Technologies Inc | 9.41M |